Evidence map›Paper›PMID 40248146›Full record

ArticleFrontiers in endocrinology2025

The prevalence of metabolic syndrome in patients with non-alcoholic fatty liver disease in primary care clinics at King Saud University Medical City, Riyadh, Saudi Arabia.

Alanoud Maan Alyousef, Doaa Zeinhom Mekawy, Yaser Yousef Bashumeel, Saleh Magdy Mohamed, Turky H Almigbal, Mohammed A Batais, Abdullah A Alrasheed

Abstract read
In one paragraph

Article in Frontiers in endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Metabolic dysfunction-associated steatotic liver disease management in Saudi Arabia: A modified Delphi-based adaptation of international standards.Saudi journal of gastroenterology : official journal of the Saudi Gastroenterology Association · 2026
    Article
  3. Article
  4. Frontiers in genetics · 2025
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Alanoud Maan AlyousefDepartment of Family Medicine, Johns Hopkins Aramco Hospital, Dhahran, Saudi Arabia.
Doaa Zeinhom MekawyDepartment of Anesthesia and Critical Care, Vision Colleges, Riyadh, Saudi Arabia.
Yaser Yousef BashumeelEndocrine and Oncology Division, Department of Surgery, Tulane University School of Medicine, New Orleans, LA, United States.
Saleh Magdy MohamedDepartment of Family Medicine, Fal-Alafia Medical Complex, Riyadh, Saudi Arabia.
Turky H AlmigbalDepartment of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Mohammed A BataisDepartment of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.
Abdullah A AlrasheedDepartment of Family and Community Medicine, College of Medicine, King Saud University, Riyadh, Saudi Arabia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Metabolic syndrome is present in a subset of individuals harboring a constellation of metabolic risk factors that heightens their likelihood of developing coronary artery disease. Non-alcoholic fatty liver disease (NAFLD) manifests through the incremental accumulation of fat within liver cells in the absence of secondary causes. NAFLD has long been recognized as the hepatic manifestation of metabolic syndrome. Our study seeks to ascertain the prevalence of metabolic syndrome among NAFLD patients at King Khalid University Hospital and to explore the factors associated with metabolic syndrome. Method and design: We conducted a retrospective study targeting 1,173 patients diagnosed with NAFLD at King Khalid University Hospital in Riyadh, Saudi Arabia, from March 2020 to March 2021. NAFLD diagnosis was made based on ultrasonographic evidence of a fatty liver, excluding other liver ailments and alcohol intake. Metabolic syndrome was defined according to the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) criteria, which require at least three of five metabolic risk factors to be present. Statistical analysis was performed using chi-square tests for categorical variables and independent t-tests for continuous variables, with a significance level set at p < 0.05. Results: Out of 1173 NAFLD participants evaluated, 38.2% met the NCEP/ATPIII criteria for metabolic syndrome. Additionally, 23.8% had at least one metabolic syndrome component coinciding with their ultrasonographically confirmed NAFLD diagnosis. The incidence of NAFLD was not linked to gender. Married individuals constituted a higher percentage (42.8%) of the NAFLD cohort. Elevated blood glucose and triglyceride levels, along with reduced HDL levels, were predominantly observed among the metabolic syndrome components in NAFLD patients. Conclusion: A significant portion of the NAFLD patient population was concurrently affected by metabolic syndrome. There exists a marked interrelationship between NAFLD and the components of metabolic syndrome. Regular metabolic disorder screenings are recommended for this patient group.

Indexed as

Metabolic SyndromeNon-alcoholic Fatty Liver DiseasePrimary Health CareAdultAgedFemaleHumansMaleMiddle AgedPrevalenceRetrospective StudiesRisk FactorsSaudi Arabiahyperglycemiametabolic syndromeNCEP/ATP-IIInon-alcoholic fatty liver diseaseSaudi Arabia

Identifiers

PMID40248146
PMCPMC12003115

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.